No Image Available
Description
Menveo is a vaccine that provides protection against four serogroups (A, C, W, and Y) of Neisseria meningitidis, the bacteria responsible for meningococcal disease.
Target Diseases
- Meningococcal disease
- including meningitis and septicemia caused by serogroups A
- C
- W
- and Y.
Dosage Schedule
Infants (2-6 months): 4 doses (3 primary doses and 1 booster) Children (7-23 months): 2 doses Individuals (2 years and older): Single dose for healthy individuals; booster may be required for continued protection.
Possible Side Effects
- Common: Pain
- redness
- or swelling at the injection site
- fever
- fatigue
- headache
- nausea. Rare: Severe allergic reactions (anaphylaxis)
- fainting
- Guillain-Barré syndrome (extremely rare).
Contraindications
- Severe allergic reaction (e.g.
- anaphylaxis) to any component of the vaccine or a previous dose of Menveo. Individuals with an acute severe febrile illness (vaccination should be postponed until recovery).
Additional Information
- Menveo is particularly recommended for travelers to areas with a high prevalence of meningococcal disease (e.g.
- the meningitis belt in sub-Saharan Africa or Saudi Arabia during Hajj and Umrah). Booster doses are recommended for high-risk individuals (e.g.
- those with certain immune deficiencies
- asplenia
- or persistent complement component deficiencies).
Storage Requirements
- Store at 2°C to 8°C. Do not freeze. Protect from light. The vaccine must be reconstituted with its diluent before administration.
